Skip to main content

Mehta Vimal's Form 4 filing

BioXcel Therapeutics, Inc. (BTAIQ) · filed Jun 18, 2024

Accession no.
0001104659-24-072999
Filed
Jun 18, 2024
Trade date
Jun 14-17, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.73K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mehta VimalCIK 0001733369Director, Officer (CEO and President), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 14, 2024Common StockMOption exerciseAcquired+2,609––46,173Direct
Jun 15, 2024Common StockMOption exerciseAcquired+3,500––49,673Direct
Jun 17, 2024Common StockSSaleDisposed−2,134$1.28−$2,731.5247,539Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 14, 2024Common StockMOption exerciseDisposed−2,609$0.00$018,266Direct
Jun 15, 2024Common StockMOption exerciseDisposed−3,500$0.00$038,500Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)